Balchem Co. (BCPC) Position Boosted by BlackRock Inc.
BlackRock Inc. lifted its position in shares of Balchem Co. (NASDAQ:BCPC) by 5.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 4,647,513 shares of the basic materials company’s stock after buying an additional 245,174 shares during the period. BlackRock Inc. owned 14.43% of Balchem worth $520,940,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Northern Trust Corp increased its position in Balchem by 2.0% during the second quarter. Northern Trust Corp now owns 458,278 shares of the basic materials company’s stock worth $44,975,000 after purchasing an additional 9,066 shares during the last quarter. SG Americas Securities LLC increased its position in Balchem by 210.8% during the second quarter. SG Americas Securities LLC now owns 8,087 shares of the basic materials company’s stock worth $794,000 after purchasing an additional 5,485 shares during the last quarter. Rhumbline Advisers increased its position in Balchem by 2.3% during the second quarter. Rhumbline Advisers now owns 85,104 shares of the basic materials company’s stock worth $8,352,000 after purchasing an additional 1,946 shares during the last quarter. Aperio Group LLC increased its position in Balchem by 11.0% during the third quarter. Aperio Group LLC now owns 15,776 shares of the basic materials company’s stock worth $1,768,000 after purchasing an additional 1,566 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Balchem by 0.6% during the second quarter. Bank of New York Mellon Corp now owns 404,678 shares of the basic materials company’s stock worth $39,715,000 after purchasing an additional 2,488 shares during the last quarter. 88.17% of the stock is currently owned by institutional investors and hedge funds.
In other Balchem news, Director Daniel E. Knutson acquired 650 shares of the company’s stock in a transaction dated Tuesday, November 13th. The stock was bought at an average price of $89.11 per share, with a total value of $57,921.50. Following the completion of the transaction, the director now directly owns 1,495 shares of the company’s stock, valued at $133,219.45. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.02% of the stock is owned by corporate insiders.
Balchem stock opened at $81.01 on Friday. Balchem Co. has a 52-week low of $70.23 and a 52-week high of $117.79. The firm has a market capitalization of $2.65 billion, a PE ratio of 32.02 and a beta of 0.94. The company has a quick ratio of 2.33, a current ratio of 3.42 and a debt-to-equity ratio of 0.27.
Balchem (NASDAQ:BCPC) last released its quarterly earnings data on Tuesday, November 6th. The basic materials company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.12. Balchem had a net margin of 15.67% and a return on equity of 14.51%. The company had revenue of $155.04 million during the quarter, compared to analyst estimates of $163.66 million. During the same quarter in the prior year, the business earned $0.63 earnings per share. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Research analysts anticipate that Balchem Co. will post 2.45 EPS for the current fiscal year.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Further Reading: Dividend Stocks – Are They Right For You?
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.